Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

YM BioSciences Inc YMI



NYSEAM:YMI - Post by User

YM BioSciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by ahnunahon Sep 07, 2009 10:42am
574 Views
Post# 16283921

Efficacy

EfficacyForgive me if this has been discussed previously on the boards:

On TheStreet.com, Aug. 14 it was said that thus far, the data has shown that Nimotuzumab doesn't have the efficacy of it's competitors.  It doesn't have their side effects as well.

Is this the general understanding of the efficacy of Nimotuzumab?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities